A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis

Study start date: December 8, 2003

Key Inclusion Criteria: * have a diagnosis of idiopathic pulmonary fibrosis (IPF) by clinical features and surgical lung biopsy or according to the American Thoracic Society criteria Key Exclusion Criteria: * have a history of significant exposure to organic or inorganic dust or drugs known to cause pulmonary fibrosis * have interstitial lung disease other than IPF * have pulmonary fibrosis associated with connective tissue disease * have other forms of idiopathic interstitial pneumonia, such as desquamative interstitial pneumonia, acute interstitial pneumonia, nonspecific interstitial pneumonia, or cryptogenic organizing pneumonia * have end-stage IPF (total lung capacity of less than 45% of predicted value) * are listed for lung transplantation at the time of study enrollment * have significant heart problems * are pregnant or lactating (if female) Other inclusion and exclusion criteria may apply.